#Pre-Exposure Prophylaxis (PrEP) Market

[wen-kexing-apologist]

Love in the Big City: Part Four- Regret, Rain, Love, and Loss

Well, it’s official. Love in the Big City, Part Four may have been short but it cemented itself as my favorite portion of the book. I asked @antonhur when he was so graciously answering questions what his favorite scene in the book was, and I can see why he said when they were lying in the rain in Bangkok; Late Rainy Season Vacation indeed. When I first started this book, I was talking with a few mutuals like @bengiyo and @lurkingshan wondering how I would feel about Young by the end of this book, because I was not a huge fan of his character in Part One. But I have very much enjoyed seeing his progress across these parts. I said already in my post about Part One that my biggest struggle with Young and the thing I think primarily contributes to the change in his friendship with Jaehee is that he cannot be serious, he cannot, does not allow himself to feel. And in Part Four, he’s finally admitting to it. 

“I was too late to put things back the way they’d been” “That is how my memories of him are preserved under glass, safe and pristine, forever apart from me” “I’ve no choice but to stand at arm’s length”

Part Four is my favorite part of this novel because Part Four is full of ghosts. Not only the ghost of Gyu-ho, but the ghost of all that came before. The rooftop party with Gyu-ho where he got plastered on whatever alcohol he could, where now he sits and drinks champagne, a ghost of both his relationship and the way he spent his college years. Going through Habibi’s wallet, a ghost of when he snuck a look at Hyung’s secrets all those years before. The text messages Young saw on Habibi’s phone about a family member with cancer, a ghost of his mother’s own diagnosis. Habibi himself, getting unexpectedly deep for only a moment before forcing the conversation away from anything real, a ghost of Young himself, and all the times he just could not bring himself to be open and honest with the people around him. 

Just like learning about the HIV diagnosis recontextualizes everything that came before it (see a wonderful essay about that by @twig-tea here) ending this book with the admission that his only wish a year ago was for Gyu-ho recontextualizes my understanding of how aware Young was about his own modus operandi. I operated under a much different assumption that Young didn’t know what he had until it was gone, that Young was not aware of how far his fears ran, of how distant he had made himself. I assumed Part Four was where Young starts to realize himself the way he’d behaved in the past and how that contributed to the downfall of his relationship to Gyu-ho. But now I think he knew it all along and he just didn’t trust us enough to say it until the end. Because I’m not quite sure even by the end of this book Young trusts us enough to be completely honest. 

I talked in my post for Part Three about HIV treatments and prevention methods, and mentioned Truvada, (generic name: emtricitabine-tenofovir) which is a pre-exposure prophylaxis medication that can be taken to prevent someone without HIV from getting HIV should they have an exposure. I mentioned there that at the time of Young’s relationship with Gyu-ho, Truvada was not available on the market in South Korea. But as it turns out, Teno-Em (tenofovir-emtricitibine), a generic PrEP medication, was available in Bangkok by 2015. In Part Four, Young describes going to a pharmacy and getting a generic medication, and he writes the errand in such a way as to make the whole thing seem shady. And maybe it was. But maybe he was just afraid, and that fear colored his own perceptions of what was going down: 

My expectation had been that the place would be hidden away in some seedy alley, but it was right there on the main street. The interior was almost the same as any other pharmacy. I showed the pharmacist a picture of the generic version of what I needed. The pharmacist, if he really was a pharmacist, took out a bottle of pills and explained to us, in English, how they worked. He said that taking just one a day at a set time was enough to perfectly prevent the disease. He really said the word “perfectly.” How could he be so confident? He added that taking two of the pills before risky intercourse and then a pill every twenty-four hours for two more doses was enough to prevent transmission. 

The facts are these: the pharmacy was on a main street, the pharmacy looked like a pharmacy, the pharmacist was able to explain how the medication worked, and the pill regimen for prevention was accurate to the pill regimen for PrEP. 

Could they have still been shady? Sure. But I think it is far more likely that Young and his historically terrible experiences with medicine have colored his perception of healthcare and placed doubt in his head over the legitimacy of this medication. Which, learning that Young and Gyu-ho have unprotected sex in Bangkok, makes me wonder if Young’s doubts about the pharmacy added another reason for him to let Gyu-ho go to Shanghai alone, if the meds they got in Bangkok weren’t real, if they didn’t work, then he likely gave Gyu-ho HV. 

Young talked about stains in this part, about permanency- the soy sauce on the mattress, the crack in the toilet and he talked about fleeting things- immediately losing the shape of Habibi’s face when he stepped outside the door, the lantern burning up and turning to ash with all the dreams, all the wishes Young had, or just the one. Regret seems to hold a permanent place in Young’s spirit, as does loss. Love is something I think he thought did not exist, or if it did then it was fleeting. He loved Jaehee and lost her, his first boyfriend died, the obsession he had over Hyung could only be described as dickmatized. But when he gave away Gyu-ho’s love, when he let Gyu-ho go to Shanghai alone, it was one of the few times in the entire novel we saw Young grieve. He fully collapsed under the weight of it all, barely leaving bed, not having the energy to maintain his typical routines, trying to root out the memories of Gyu-ho in his head by writing him out, and killing him over and over and over again. 

I find myself stuck, thinking about what is perhaps my favorite line in the book: 

“Sometimes his very existence to me is the existence of love itself”

Gyu-ho’s existence is Young’s idea of love; to kill Gyu-ho, to remove him from existence is to kill Young’s idea of love. “The made-up Gyu-ho in my writing got hurt or died many times, and is always resurrected, as if love saves his life- whereas the real Gyu-ho lives and breathes and keeps moving on.” Young’s regret is a permanency in his life, just as his love for Gyu-ho is a permanency. All he wished for was Gyu-ho, but Young’s inability to be honest, deeply, emotionally honest, all the fear, all the emptiness, all the pain got in the way. I am not a person who minds a melancholy end, regret, remorse, grief, love. These are all a part of life. The only thing I hope is that one day Young can lay down in the pouring rain and feel peace the way Gyu-ho did that day in Bangkok.

[gumjrop]

The Weather

A study in Clinical Infectious Diseases reported “that the risk of developing symptomatic illness within 14 days was 5 times greater when contacts were exposed to an asymptomatic [COVID]-positive child in their household.” Nearly 11% of household contacts developed symptoms within 14 days of exposure. The study also found, during a 3-month follow-up, that 6 out of 77 asymptomatic children developed Long COVID. The likelihood of developing symptoms from asymptomatic exposure is higher than we might expect. Continue to spread awareness of asymptomatic spread and advocate for increased infection control measures at your local schools.

COVID wastewater levels are decreasing. As of 3/29/24, New Mexico is “Very High,” Arkansas and Kentucky are “High,” and the rest of the states are “Moderate” to “Low” levels of SARS-CoV-2 detected in wastewater. 

Wastewater levels continue to show a downward trend in the provisional data (gray shaded area) in all regions. The national wastewater levels are overall indicated as “Low.” While lower wastewater levels indicate decreased spread, it is important to continue to take precautions against infection. Holidays and spring breaks may bring people in closer proximity, so be sure to wear a mask to protect yourself and your community.

Wins

As we work to take more actions against the removal of vital public health measures, we remind you that you can still watch the recording of the People’s CDC press conference from March 13 and read the press release here. We would also like to remind you of the pre-proof of the People’s CDC External Review in the American Journal of Preventive Medicine Focus. The publication highlights the shortcomings of the CDC’s approach to public health and recommends a more equitable pandemic response.

News sources have published articles about the frustrations of people who continue to take COVID precautions. Time Magazine published an article presenting “both sides,” highlighting protest from people working with the CDC and concern from citizens and experts alike. While we are glad to see our voices be published in popular media, we are also saddened that “returning to normal” under economic and political pressure is so valued.

Treatments

Invyvid has received an FDA emergency use authorization for Pemgarda, a pre-exposure prophylaxis (PrEP) for people with immunocompromising conditions. Pemgarda is approved for people 12 and older with moderate to severe immunocompromise who are less likely to produce an adequate immune response to COVID vaccination alone. According to a press release from Invyvid, Pemgarda will release to market “imminently.”

Pre-exposure prophylaxis is commonly used for folks at high risk for exposure to HIV. As access to PrEP for HIV has been instrumental in keeping people safe, we hope that PrEP for COVID will be a useful tool for our community members with immune compromise. We also urge you to continue to wear high-quality masks and take other precautions to protect those most vulnerable.

Long COVID

People Magazine recently published an article highlighting an essay by Ziyad Al-Aly, physician and clinical epidemiologist, that pools data from several studies showing that COVID infection has lasting impacts on brain health. The review points out several impacts to cognitive functioning, including memory loss, spatial reasoning, and planning. Additionally, imaging studies have shown significant impact to brain tissue from inflammation, among other processes. The publication may be validating to those who experience lower cognitive function following COVID infection, including brain fog and memory dysfunction.

Take Action

We know that taking precautions–including masking, testing, and improving air quality–helps prevent the spread of airborne viral infection. Introducing more stringent precautions slowed outbreaks in the hematology ward of a hospital. The CDC recently released tips to improve ventilation. Help us urge the CDC to take other measures, including reinstating isolation periods. 

Additionally, the home Test to Treat program is ending in April 2024. The program provides un-or-underinsured adults with free COVID and flu tests. If a participant in the program tests positive, they can also receive free healthcare via telehealth services. Join us to help save the program that helps so many at-risk people!

[beardedmrbean]

1. Au revoir les trottinettes: Paris ban on shared e-scooters takes effect tomorrow

Banned from Paris by popular vote, shared e-scooters will roll for the last time in France's capital on Thursday 31 August, marking the end of five years of their controversial presence. Read more.

2. Tackling Belgium’s drug problem: Legalising cannabis is ‘common sense,’ says Economy Minister

A solution to the drug and security problem in Belgium's bigger cities, such as Brussels and Antwerp, could be legalising the sale and use of cannabis, according to Federal Economy and Employment Minister Pierre-Yves Dermagne. Read more.

3. Cinema tickets for €1 in Brussels and Wallonia in September

From 1-30 September, 21,000 independent cinema tickets will be available for the price of €1 across 34 cinemas in Brussels and Wallonia, as part of this year's edition of J’peux pas, j’ai cinéma. Read more.

4. Will the Belgian property market cool down enough to make buying more affordable?

As interest rates have reached record-high levels, the property market in Belgium has cooled down. The Brussels Times asked Bart van Opstal of the Federation of Notaries what this means for people looking to buy property at the moment. Read more.

5. Harder to trick: New alcohol check procedure to increase chance of being caught

The alcohol breath test procedure currently in place for checks on the road in Belgium will be adapted so that testing is quicker and more efficient for catching offenders. It is expected that the changes will increase the number of people caught. Read more.

6. The price of a healthy life: How to access PrEP in Belgium as an expat

PrEP (pre-exposure prophylaxis) can be a powerful tool in reducing the chances of HIV infection in at-risk groups. When taken as prescribed, it is up to 99% effective at reducing infection. Read more.

7. Open-air party at Rogier denounced as 'a commodification of public space'

The news of a 10-hour marathon electronic dance open-air being organised in the centre of Brussels will be music to the ears of party-goers, but one action group has heavily criticised it. Read more.

[foreverlogical]

A federal appeals court panel appeared skeptical on Tuesday of calls to impose a nationwide freeze on Obamacare’s rules for no-cost coverage of preventive care while litigation continues — a move the Biden administration warned would threaten access to a range of services for millions of people on employer-sponsored insurance and Obamacare’s individual market.

Both sides in the case agreed that the individual Texas businesses that sued over the mandate should be shielded from it while the case makes its way through the courts. But they split on whether more harm would be caused by keeping the current coverage rules intact for everyone else in the country or by suspending them nationwide.

Attorneys representing the Texas employers and individual workers challenging the policy argued that because 

the United States Preventive Services Task Force is made up of outside experts who are not Senate-confirmed or overseen by Senate-confirmed government employees, their recommendations of what preventive services should be covered by insurance — from syphilis tests to depression screenings — must be “set aside” and can’t be enforced.

Their suit also claims the Obamacare requirement for insurance to cover the pre-exposure prophylaxis pill used to prevent transmission of HIV — known as PrEP — violates the religious rights of the challengers. In their legal briefs, they equated covering the highly effective medication with encouraging homosexuality and promiscuity.

The merits of those legal arguments didn’t come up in Tuesday’s hearing before the 5th U.S. Circuit Court of Appeals in New Orleans, which focused squarely on whether the nationwide freeze of the Obamacare mandate a lower court ordered in March went too far.

That ruling, Justice Department attorney Alisa Klein told the court, was a “legal error” that “extinguished the rights of about 150 million people who are not parties to the case.”

Klein urged the appeals court judges to consider the “balance of equities,” arguing that there would be no harm done to the already-protected plaintiffs by putting the nationwide injunction on hold, but great harm done to everyone else if they failed to do so.

“It can’t be overstated how important the guarantee of cost-free access is when patients go to get their mammograms and colonoscopies,” she said. “We’re talking about 50 different types of care.”

The attorney for the conservative challengers, Jonathan Mitchell, responded that the nationwide ruling was appropriate because “agency actions must be set aside if they are unlawful.”

Mitchell — the architect of the six-week abortion ban Texas imposed before Roe was overturned — attempted to reassure the judges that imposing a nationwide injunction wouldn’t cause harm because insurers are unlikely to drop coverage of preventive care services while the case is still in process.

The judges on the appeals court panel seemed unconvinced.

Leslie Southwick — an appointee of former President George W. Bush — called that assertion “speculative” and said it was “very unusual” to be asked to rule on “our sense of how insurance companies would react.”

“I’m not sure what we have to go on,” he said.

The judges also grilled Mitchell on whether a win for his side would solve his clients’ problem — a legal threshold known as “redressability.” When Mitchell argued that individual workers he represents who are refusing to buy insurance because of the PrEP coverage requirement would be able to get covered if the mandate were lifted, Judge Stephen Higginson noted that the workers’ own affidavits “don’t say that.”

Higginson — an appointee of former President Barack Obama — pointed out that only one of the four workers came anywhere close to making that claim, and that he expressed “a desire to buy insurance, not a specific intent.”

Mitchell acknowledged that there’s no “iron-clad guarantee” his clients would buy health insurance if courts blocked the Obamacare mandate.

In closing, the judges urged both him and the DOJ to try to broker a compromise that would more narrowly tailor the nationwide ruling without infringing on the rights of the plaintiffs.

Tuesday’s hearing was the latest in a months-long saga over the preventive care mandate that’s been in place for more than a decade.

Texas District Court Judge Reed O’Connor — the author of several rulings against pieces of Obamacare — issued a nationwide ruling in March for the challengers, striking down all of the decisions made by the United States Preventive Services Task Force since 2010 about what insurers must cover without cost sharing.

In May, the 5th Circuit Court issued an administrative stay of that lower court ruling — keeping the current coverage rules in place while the case proceeds.

Public health groups warn of serious consequences if O’Connor’s ruling is upheld — citing research showing that even small out-of-pocket costs deter many people from seeking preventive care, leading to sicker patients and more costly treatments. Medical experts are particularly worried that coverage rollbacks would exacerbate already record rates of sexually transmitted diseases by making testing and treatment services unaffordable for vulnerable populations.

Many major insurers have pledged to maintain preventive care at no cost to patients for the time being no matter what courts decide, but experts fear that patients could eventually be hit with out-of-pocket charges should the 5th Circuit and Supreme Court side with the challengers.

The case also throws more than two-dozen new recommendations the federal task force is currently weighing in jeopardy, rules that could expand coverage of everything from prenatal care to speech therapy to osteoporosis.

[qnewsau]

'Plan ahead': Crucial advice as PrEP shortage hits Australia

New Post has been published on https://qnews.com.au/plan-ahead-crucial-advice-as-prep-shortage-hits-australia/

'Plan ahead': Crucial advice as PrEP shortage hits Australia

Australia is experiencing a shortage of a HIV prevention medication PrEP and our sexual health organisations are urging those who rely on it to plan ahead to avoid running out.

Pre-exposure prophylaxis, or PrEP, was a “game changing” antiretroviral drug helping people at high risk of HIV infection. Last year, at least 45,000 Australians took PrEP.

A spokesperson for the Therapeutic Goods Administration (TGA) confirmed all four of Australia’s pharmaceutical suppliers of tenofovir/emtricitabine combination tablets are experiencing disruptions.

The TGA spokesperson said suppliers of the drug have reported issues including manufacturing, “commercial changes” and viability. All but one of the four PrEP products on the market will return to supply between mid-October and mid-November, the TGA says.

‘Don’t leave restocking to the last minute’

ACON’s HIV and sexual health director Matthew Vaughan said while the situation is concerning, he’s confident the situation will be resolved in the coming months.

“If you are currently taking PrEP, please do not leave restocking your medication to the last minute,” he said.

“Given the current situation, you may need to visit more than one pharmacy to find a supply. There may be limitations on how many bottles of PrEP you are able to obtain from the pharmacy.

“Please plan ahead to ensure you don’t run out.”

He advised anyone unable to obtain PrEP through pharmacies to access it online, with information available at the PrEP Access Now website.

Matthew Vaughan suggested anyone taking daily PrEP who isn’t having sex regularly or frequently can conserve medication and maintain the same level of protection with an on-demand dosing schedule.

‘Shortage is unlikely to last very long’

In Victoria, Thorne Harbour Health CEO Simon said in the last decade an “incredible number” of gay, bisexual, and other men have sex with men have “embraced PrEP as their preferred HIV strategy.”

“So when we hear about a shortage, it certainly raises concerns,” he said.

“On-demand PrEP is also an option for guys looking to make the PrEP they currently have last longer.

“Our communities aren’t unfamiliar with using personal importation, and we’ve got great community partners like PrEP Access Now that have been helping our communities navigate that process for years.

“The reality is that this shortage is unlikely to last very long, so we may just need to employ these other options in the meantime.

“Thinking about what HIV prevention strategies work for your circumstances – is always a worthwhile exercise.”

For the latest LGBTIQA+ Sister Girl and Brother Boy news, entertainment, community stories in Australia, visit qnews.com.au. Check out our latest magazines or find us on Facebook, Twitter, Instagram and YouTube.

[enterprisewired]

Gilead’s Breakthrough HIV Prevention Shot Shows Promise

Source – PinkNews

Successful Trial Results

Gilead Sciences announced a groundbreaking achievement on Thursday: its experimental lenacapavir shot, administered twice-yearly, demonstrated 100% effectiveness in HIV Prevention in a late-stage clinical trial. The interim analysis revealed that none of the approximately 2,000 women who received the shot contracted HIV, prompting the trial’s independent data monitoring committee to recommend unblinding the study and offering lenacapavir to all participants. Those in the control group received standard daily pills.

Market and Investor Response

Following the promising results, Gilead’s stock surged by approximately 7% on Thursday. The pharmaceutical giant views these findings as a significant advancement towards expanding its HIV treatment portfolio and introducing a new form of pre-exposure prophylaxis (PrEP) to the market.

Future Prospects and FDA Approval

Before seeking approval from the FDA, Gilead plans to replicate these results in ongoing Phase 3 studies, including one involving men who have sex with men, with data expected later this year or early next year. If successful, Gilead aims to launch lenacapavir for PrEP as early as late 2025, pending regulatory approval.

Impact on HIV Prevention Landscape

Gilead’s Truvada, introduced over a decade ago, was the first FDA-approved PrEP, revolutionizing HIV prevention with daily pills. However, the market is now shifting towards longer-acting alternatives like injectable shots, which offer convenience and potentially higher adherence rates among users.

PrEP has been shown to reduce the risk of HIV transmission significantly—from sex by 99% and from injected drug use by 74% when taken correctly. Despite its efficacy, adoption rates in the U.S. remain low, with just over one-third of eligible individuals utilizing PrEP, according to the CDC.

Broader Implications and Access Challenges

Health policymakers and advocates welcome longer-acting PrEP options as potential game-changers in combating HIV globally. These alternatives are seen as crucial for individuals who find daily pills impractical or undesirable due to lifestyle factors. Activists urge Gilead to ensure equitable access to lenacapavir, especially in regions with high HIV incidence and limited resources.

Gilead has faced scrutiny over the pricing of its HIV medications, including Descovy, which costs $26,000 annually. In response, the company plans to address access concerns for lenacapavir in affected countries, as part of its commitment to global health equity.

The success of lenacapavir represents a significant milestone in HIV prevention, potentially expanding treatment options and improving outcomes for individuals at risk worldwide. As Gilead advances towards regulatory approval, stakeholders remain optimistic about the prospect of transforming HIV prevention strategies with innovative, long-acting therapies.

Curious to learn more? Explore our articles on Enterprise Wired

[bhushans]

Bridging the Gap: How the Global Prophylactic HIV Drugs Market is Expanding Access to Care

The prophylactic HIV drugs market is witnessing significant expansion, with robust growth projected in the coming decade. In 2023, the market size reached an estimated USD 32,516.1 million, driven by increased investment in HIV research and development, rising drug approvals, and a surge in HIV incidence rates.

According to Future Market Insights, the market is forecasted to expand at a Compound Annual Growth Rate (CAGR) of 4.1% between 2023 and 2033, reaching a valuation of approximately USD 48,822.4 million by 2033. This growth trajectory underscores the critical importance of prophylactic HIV drugs in combating the global HIV/AIDS epidemic.

Request Your Detailed Report Sample With Your Work Email: https://www.futuremarketinsights.com/reports/sample/rep-gb-9582

Global sales of HIV prophylaxis drugs are projected to reach a value of about USD30 billion by 2021. Owing to growing awareness of HIV and the rising prevalence of HIV infection worldwide, As for AIDS prevention, between 2022 and 2032, the market for preventative HIV drugs grew at a compound annual growth rate (CAGR) of 4%, reaching USD 40 billion in 2028.

HIV has been a major global cause of death for many years, impacting millions of people. People whose immune systems are compromised by the virus are more susceptible to a range of ailments and cancers. HIV can be controlled even when there isn’t a long-term cure by expanding access to adequate care, diagnosis, medication, and prevention.

Prophylactic HIV Drugs: A Powerful Prevention Tool

Effective management techniques are available for HIV, even though a long-term cure is still unattainable. One of the most important aspects of fighting the virus is expanding access to care, diagnosis, treatment, and prevention services. HIV prevention medications are becoming an essential weapon in the fight against HIV infection. These cutting-edge treatments work especially well at preventing HIV transmission through drug injection and sexual contact.

Focus on Pre-Exposure Prophylaxis (PrEP):

Pre-Exposure Prophylaxis (PrEP), one of the preventive HIV medications, is becoming increasingly popular because of its great effectiveness. The risk of HIV infection from sex and injectable drug use can be considerably decreased with PrEP, according to the Centers for Disease Control and Prevention (CDC), by 74% and 99%, respectively. The extraordinary efficacy of PrEP is spearheading a global movement for its expanded usage.

Market Competition:

Some of the prominent players operating in the global market are-

Gilead Sciences, Inc

Merck Sharp & Dohme Corp.

Merck & Co. Inc.

Mylan NV

Cipla Inc.

Genentech Inc.

Bristol-Myers Squibb Company

Johnson & Johnson Health Care Systems Inc

Pfizer Inc.

GalaxoSmithKline PLC

Notable Developments of the Key Players in the Market

In April 2023, Merck & Co (MRK.N) confirmed that it is going to buy Prometheus Biosciences Inc (RXDX.O) for about $10.8 billion, by picking up a promising experimental treatment for ulcerative colitis and Crohn’s disease and building up its presence in immunology.

In November 2022, Merck, known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, might acquire Imago for US$ 36.00 per share in cash for around total equity value of US$ 1.35 billion.

Key Companies Profiled:

Gilead Sciences, Inc

Merck Sharp & Dohme Corp.

Merck & Co. Inc.

Mylan NV

Cipla Inc.

Genentech Inc.

Bristol-Myers Squibb Company

Johnson & Johnson Health Care Systems Inc

Pfizer Inc.

GalaxoSmithKline PLC

Key Segments Profiled in the Prophylactic HIV Drugs Industry Survey:

By Drug Class:

Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTI)

Integrase Inhibitor

By Distributional Channel:

Hospital Pharmacies

Retail Pharmacies

Mail Order Pharmacies

Drug Stores

By Region:

North America

Latin America

Western Europe

Eastern Europe

Asia Pacific Excluding Japan

Japan

The Middle East and Africa

[lovelypol]

Breaking Barriers: The Ongoing Fight Against HIV Type-1 - A Look into the Market for Hope and Progress! 🌈💪

Hello, Tumblr community! Let's discuss the ongoing efforts in the battle against HIV Type-1 and the incredible progress in the market dedicated to providing hope, treatment, and support for those affected. 🌍🏥

💡 What's the buzz all about? The HIV Type-1 Market is all about advancing research, treatment, and awareness to combat one of the most significant public health challenges of our time. It's a market with a mission! 💊🔬

Here's why it's essential to stay informed:

1️⃣ Lifesaving Medications: The market offers antiretroviral drugs that help manage HIV, enabling those affected to lead healthy lives. 2️⃣ Prevention Strategies: Ongoing research focuses on developing new prevention methods, including vaccines and PrEP. 3️⃣ Community Support: Advocacy and awareness campaigns work tirelessly to break down stigmas and offer support.

🌟 Leading Innovations: 🔍 Antiretroviral Therapy (ART): These drugs suppress the virus and help prevent the progression of HIV. 💉 Pre-Exposure Prophylaxis (PrEP): An innovative approach for high-risk individuals to prevent HIV transmission. 🌈 Supportive Communities: Non-profits, clinics, and organizations offer vital support to those affected by HIV.

💖 The future is filled with hope! As technology and research advance, the HIV Type-1 Market is poised to make even greater strides in the fight against this virus, bringing us closer to a world without HIV. Let's celebrate the tireless work of healthcare professionals, researchers, and advocates dedicated to this mission. 🌈💕💪

Join the conversation, raise awareness, and show your support for the ongoing battle against HIV Type-1. Together, we can make a difference and stand with those affected by this virus. 🏳️‍🌈❤️🔬

[healthcaretoday1]

Exploring HIV Treatment: Revealing Antiretroviral Medications, Obstacles, and Emerging Directions

Antiretroviral therapies (ART) have revolutionized the landscape of HIV treatment, offering a beacon of hope for individuals living with the virus. These medications effectively inhibit HIV replication, allowing for longer, healthier lives. Continuous advancements in ART have made managing HIV a journey marked by hope and progress.

Write to us at enquire@grgonline.com Learn how GRG Health is helping clients gather more in-depth market-level information on such topics

Achieving Effective Viral Suppression: A Cornerstone of ART

The primary objective of ART is to attain and sustain viral suppression. By reducing the viral load to undetectable levels, ART not only enhances the quality of life for those with HIV but also prevents viral transmission to others. This dual benefit has spurred global efforts to expand ART accessibility.

Navigating Challenges: Adherence and Resistance

Despite the transformative impact of ART, challenges persist. Strict adherence to the medication regimen is crucial for success. Skipping doses or inconsistent use can lead to viral resistance, wherein the virus mutates and becomes resistant to the drugs. Overcoming these hurdles demands ongoing support, education, and personalized treatment plans.

Stigma and Access: Barriers to Receiving Care

The stigma surrounding HIV remains a significant obstacle to treatment access. Fear of discrimination and a lack of awareness can deter individuals from seeking diagnosis and treatment. Furthermore, unequal access to ART in various regions underscores the need for global initiatives to improve availability and affordability.

Synergistic Approaches: Augmenting Effectiveness

Combination therapies, also known as antiretroviral regimens, are central to contemporary HIV treatment. These regimens integrate multiple antiretroviral drugs to target the virus at various stages of its life cycle. This strategy enhances treatment effectiveness, minimizes the risk of resistance, and offers more flexible dosing options.

Future Prospects: A Beacon of Hope

The future of HIV treatment is characterized by promising trends that inspire optimism for enhanced care and outcomes. Long-acting injectable ART, requiring fewer doses while maintaining viral suppression, is poised to be a game-changer. Additionally, advancements in prevention strategies, such as pre-exposure prophylaxis (PrEP), contribute to global efforts to reduce new infections.

Holistic Care: Beyond Medications

While antiretroviral therapies are pivotal, comprehensive care is essential for individuals with HIV. This encompasses regular medical monitoring, mental health support, nutritional guidance, and addressing co-existing conditions. A holistic approach ensures that individuals attain optimal health and well-being.

Conclusion: A Journey of Resilience, Progress, and Hope

The journey of navigating HIV treatment is one marked by resilience, progress, and hope. Antiretroviral therapies have transformed the lives of those affected by HIV, providing effective viral suppression and prevention. Although challenges persist, advancements in treatment and prevention strategies, coupled with a growing commitment to education and awareness, pave the way for a future where HIV can be managed confidently and optimistically.

[linapoletti]

In its activism and agitation, ACT UP was often fighting against inherent biological limits as much as governmental policies. No amount of rage and public awareness could by themselves cure a disease. To this day, despite decades of well-funded research, there is still no vaccine for HIV-AIDS. The drugs have gotten more sophisticated, but in principle, the treatment remains the same as it was with AZT: AIDS is still treated as a chronic condition to be managed with antiretrovirals.

With the appearance of Pre-Exposure Prophylaxis, or PrEP, in 2012, it became common to prescribe antiretrovirals not just for AIDS patients, but also as a daily preventive measure for healthy sexually active gay men. This trend of medicalizing the healthy hasn’t been unique to homosexuals, of course. As the physician and critic of medicine Seamus O’Mahony has written, “Pharma’s single greatest idea was to move its focus from the sick to the well, thus creating vast new markets of ‘patients’ requiring lifetime treatment with drugs.” For example, healthy people can be redefined as being at risk of future disease based on measures like blood pressure or cholesterol and then prescribed medication they must take for the rest of their lives to keep the risk at bay.

The increased medicalization of everyday life in recent decades hasn’t been a purely top-down process. However unwittingly, AIDS activists played a part in bringing it about. ACT UP provided a model for patients organizing themselves into a political constituency to raise awareness and demand drugs for their condition. Pharma is an enormously powerful industry, but by funding patient-support groups, it can present itself as the voice of the powerless.

During the Covid pandemic, many activists demanded that medicine and public health be accorded massive power over our daily lives. Notable among them was Yale epidemiologist and public intellectual Gregg Gonsalves, a veteran of ACT UP. As a young man, Gonsalves spoke of the need for activists to prod science in the right direction on AIDS research. More recently, he became a vociferous advocate of mask and vaccine mandates to fight Covid.

But nowhere is ACT UP’s legacy more apparent than in the relationship between contemporary transgender activism and transgender medicine. In this politically charged domain, the division between science and activism has broken down almost completely. Activists have managed to get the medical establishment to adopt the so-called affirmative model for gender dysphoria. According to this model, if patients experience distress about their secondary sex characteristics, the role of medical professionals is to affirm them as having a transgender identity and put them on path to hormones and surgeries.

In their rhetoric and style, trans activists bear a close resemblance to ACT UP. Both groups have argued that withholding access to experimental drugs amounts to deliberate murder, and the ubiquitous talk of “trans genocide” echoes ACT UP’s rhetoric from decades ago. Trans activists, like AIDS activists in their day, see themselves as a radically oppositional force, but their demands happen to coincide with the interests of a pharmaceutical industry always seeking out new groups of lifelong customers and novel rationales for loosening regulatory oversight.

In one crucial respect, trans activism goes well beyond ACT UP’s work. While Kramer and others exaggerated the dangers of AIDS to the population at large, it was certainly true that many people were dying or desperately sick of the disease in the group’s heyday. By contrast, trans activists’ claims about looming death are almost entirely a rhetorical tactic. We see this, for example, in the routine claim that dysphoric youth will all kill themselves if they aren’t allowed to transition. As a statistic, this is a fabrication, but suicidal ideation is contagious; by endlessly repeating it, activists make it more likely to be true. The assertion is better understood as a threat than a statement of fact.

[techsciresearch]

United States Pre-Exposure Prophylaxis Market to Grow with an Impressive CAGR until 2026 | TechSci Research

Increasing awareness about HIV/AIDS is driving the growth of United States Pre-Exposure Prophylaxis (PrEP) Market, in the forecast period, 2022-2026.

According to TechSci report on, “United States Pre-Exposure Prophylaxis (PrEP) Market By Drug Type (Truvada v/s Descovy), By Route of Administration (Oral v/s Topical), By Region, Competition Forecast & Opportunities, 2026”, United States pre-exposure prophylaxis (PrEP) market has shown promising growth in historical years until 2020 and is expected to continue its growth in upcoming forecast years 2021 to 2026. The United States pre-exposure prophylaxis (PrEP) market owes its growth to the factors like growing awareness about precaution against HIV viral infection and preventive therapeutics.

The surging demand for the effective precautionary methods or therapeutic products like PrEP drugs for the patients under the risk of contracting HIV infection in future is driving the growth of the United States pre-exposure prophylaxis (PrEP) market in the upcoming five years.

Also, rapidly increasing instances of HIV among the MSM population of the country have scared the population and the government of the country to a large extent thus the population is inclined toward regular checkups and diagnostic tests that can help in deciding the population for the preventive treatment thus supporting the growth of the United States pre-exposure prophylaxis (PrEP) market in the next five years.

Browse over XX market data Figures spread through 70 Pages and an in-depth TOC on "United States Pre-exposure prophylaxis (PrEP) Market"

https://www.techsciresearch.com/report/united-states-pre-exposure-prophylaxis-market/8124.html

Additionally, increasing MSM population of the country is further substantiating the growth of the United States pre-exposure prophylaxis (PrEP) market in the future five years. The MSM population is highly susceptible to HIV infectious diseases and are supporting the market growth in the future. Private fundings, and governmental aids with favorable schemes are supporting the robust growth of the United States pre-exposure prophylaxis (PrEP) market in the forecast period.

The United States pre-exposure prophylaxis (PrEP) market segmentation is based on drug type, route of administration, competitional landscape, and regional distribution. Based on drug type, the market is further bifurcated into Truvada and Descovy. Truvada is anticipated to hold the largest revenue shares of the market and dominate the market segment in the upcoming five years on the account of its high adoption and increased demand since the drug is marketed since early 2019.

Also, higher efficiency and reduced risk of acquiring HIV/AIDS infection comparatively is anticipated to support the growth of the Descovy drug type and thus support the growth of the United States pre-exposure prophylaxis (PrEP) market in the next five years. Truvada is a combination of two drugs, tenofovir disoproxil and emtricitabine. Truvada is a fixed dose of combination of antiretroviral medication that has proven effect on the treatment and prevention of HIV virus.

Download Sample Report @ https://www.techsciresearch.com/sample-report.aspx?cid=8124

Customers can also request for 10% free customization on this report.

The drug is administered along with the recommendation of following safer sex practices thus increasing awareness among the population. Tenofovir alafenamide is available in the market under the brand name of Descovy. It is a Hepatitis B virus inhibitor that also acts against HIV viral infection.

On the basis of route of administration, the market segments are defined as oral, and topical. Oral administration of the drugs in anticipated to hold the largest revenue shares of the market and dominate the market segment in the next five years on the account of availability of the drug in pill form.

Also, oral administration is more convenient for daily/ regular administration. Maintaining the dosage is also favorable for oral route of administration and thus supports the growth of the sub-segment and drives the growth of the United States pre-exposure prophylaxis (PrEP) market in the upcoming five years.

A partial list of major market players of the United States pre-exposure prophylaxis (PrEP) market includes:

Gilead Sciences, Inc.

Teva Pharmaceuticals USA, Inc.

Merck & Co., Inc.

Cipla Inc

Bristol-Myers Squibb Company

Genentech, Inc

These market players along with new market entrants, are focused on extensive research and bringing innovative and advanced products. Technologically advanced manufacturing of the pharmaceutical products and therapeutic processes would aid in decreasing the cost of the production and aid the players in managing their investments. Moreover, initiatives from the government and private fundings would support the United States pre-exposure prophylaxis (PrEP) market growth indirectly.

Press Release: https://www.techsciresearch.com/news/6705-united-states-pre-exposure-prophylaxis-market.html

“Young population in the United States is getting highly aware of the increasing instances of HIV virus and their awareness is boosting the growth of the United States pre-exposure prophylaxis (PrEP) market in the upcoming five years. Increasing research and innovative therapeutic product development is further driving the growth of the United States pre-exposure prophylaxis (PrEP) market in the future five years. Through researched studies and surveys authoritative bodies are creating awareness among black and Hispanic population about them being more susceptible to HIV infection and further aiding the market growth in next five years,” said Mr. Karan Chechi, Research Director with TechSci Research, a research based global management consulting firm.

“United States Pre-Exposure Prophylaxis (PrEP) Market By Drug Type (Truvada v/s Descovy), By Route of Administration (Oral v/s Topical), By Region, Competition Forecast & Opportunities, 2026” has evaluated the future growth potential of United States pre-exposure prophylaxis (PrEP) market and provides statistics & information on market size, structure and future market growth. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment decisions. Besides, the report also identifies and analyzes the emerging trends along with essential drivers, challenges, and opportunities in United States pre-exposure prophylaxis (PrEP) market.

Browse Related Projects:

United States Smart Hospitals Market By Component (Hardware, Software System, Services) By Technology (Cloud Computing, Artificial Intelligence, Wearable Technologies, Others) By Connectivity (Wired v/s Wireless) By Application (Remote Medicine Management, Medical Connected Imaging, Medical Assistance, Electronic Health Record, Others) By Services Offered (General Services, Specialty, Super Specialty), By Region, Company Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/united-states-smart-hospitals-market/8037.html

Vietnam Telemedicine Market By Component (Services, Software, Hardware), By Deployment Mode (Cloud v/s On-Premises), By Type (Tele-Hospitals, mHealth, Tele-Homes), By Technology (Store & Forward, Real Time, Others), By Application (Tele-Psychiatry, General Consultations, Tele-Radiology, Tele-Pathology, Others), By End User (Payer, Provider, Patients), By Region, Competition Forecast & Opportunities, 2026

https://www.techsciresearch.com/report/vietnam-telemedicine-market/7899.html

Contact

Mr. Ken Mathews

708 Third Avenue,

Manhattan, NY,

New York – 10017

Tel: +1-646-360-1656

Email: sales@techsciresearch.com

Website: https://www.techsciresearch.com/

For More Market Research Blogs Visit: https://techsciblog.com/

[rapeculturerealities]

When PrEP—or pre-exposure prophylaxis, a daily pill that protects against HIV—came on the U.S. market in 2012, it captured the attention primarily of men who have sex with men. According to the Food and Drug Administration, the first PrEP pill, Truvada, provides over 90 percent protection from sexually acquiring HIV when taken daily. Logically, this is a boon to women who may not be able to insist on condoms or prefer not to use them. So why did the FDA recently approve a new PrEP pill without approving it for cisgender women’s use?

Truvada isn’t cheap. Without insurance or other cost breaks, one month’s worth costs about $1,800 in the United States. The price is much lower in countries where essential medicines’ prices are capped by government.

Given its cost and the fact that Truvada was marketed primarily to gay men, it is not surprising that 95 percent of Americans using PrEP in 2016 (the last year data was available) were men. More than two thirds (69 percent) of U.S. PrEP users were white, over half (56 percent) lived in a Western or Northeastern state, and 81 percent of all PrEP prescriptions were covered by commercial insurance. In other words, PrEP was (and still is) mostly used by affluent white men.

When PrEP was being developed more than a decade ago, two major clinical trials were conducted to assess its effectiveness: one enrolling 4,758 heterosexual couples and one enrolling 2,499 HIV-negative gay men and transgender women. High levels of protection were achieved in both trials. Findings confirmed that Truvada is highly effective for cis women, even though it may be slightly “less forgiving” than for cis men if doses are missed. Research shows that one of the two components in Truvada is not absorbed by vaginal tissue as readily as by rectal tissue. Missing doses can cause the level of this drug to drop in the vagina, possibly reducing the user’s protection. So consistent, daily use of Truvada is more important for cis women to ensure full protection.

read more

[typhlonectes]

There’s a very successful little blue pill on the market. It’s highly effective, it benefits thousands of people, and it can transform your love life. No, it’s not Viagra. It’s Truvada, also known as pre-exposure prophylaxis (PrEP), and it is 99 percent effective at preventing HIV infections.

PrEP is so good it has almost eradicated new HIV infections in Australia and helped New York achieve historic lows in HIV diagnoses. Now, doctors and policy makers are working to expand access to the drug and to refine delivery methods that are easier and more personalized for users’ needs. “There’s a lot of interest in what we can do with PrEP to meet consumers where they are, find the right formulation for each type of consumer,” says John Brooks, a senior medical adviser at the Centers for Disease Control and Prevention’s Division of HIV/AIDS Prevention...

[pozmagazine]

Pharmacies at Walmart stores, Sam’s Clubs and Albertsons Companies will donate their dispensing services to people in the federal HIV prevention program “Ready, Set, PrEP,” according to an announcement by the Department of Health & Human Services (HHS), which oversees the program. This means the pharmacies will refill participants’ prescriptions for free.

Currently, the Food and Drug administration has approved two forms of pre-exposure prophylaxis, or PrEP: Truvada and Descovy. Both are highly effective regimens of daily tablets and are manufactured by Gilead Sciences. (For more details, see “What’s the Difference Between Truvada and Descovy for PrEP?”)

Walmart stores and Sam’s Clubs operate over 5,000 pharmacies, and Albertsons Companies includes pharmacies in the supermarkets Albertsons, Safeway, Vons, Jewel-Osco, Shaw’s, Acme, Tom Thumb, Randalls, United Supermarkets, Pavilions, Star Market, Haggen, Amigos United, Market Street United and Carrs.

[asphealth]

"Pre-exposure prophylaxis, also known as PrEP, is a treatment for those who have a high risk of getting HIV by using intravenous drugs or intercourse. The Centers for Disease Control (CDC) recommends this as part of their HIV preventive approach. It is available only as a cure in several places. The FDA-approved PrEP drug, which is marketed under the trade names Truvada and Descovy, combines the drugs tenofovir and emtricitabine and must be properly administered to prevent HIV from taking root in your body. Click here (https://asphealth.co/blogs/prep-for-hiv-prevention-and-how-it-works-and-its-side-effects/) to read more about it in detail."